文献速递卫生政策与健康促进

确定通往全民健康覆盖的效率路径:基于预期寿命增长与卫生支出的174国成本效果阈值

Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures.
PubMed 文献 · Lancet Glob Health · 2023-01-01

研究构建概念框架,以人均卫生支出和出生预期寿命为基础估算成本效果阈值,并利用世界银行2010-19年数据按收入水平预测174国的卫生支出与预期寿命变化,经验性推导出各国阈值。每质量调整生命年阈值介于87美元(刚果民主共和国)至95958美元(美国)之间。作者认为该方法可为各国资源分配决策提供参考,且结果低于许多国家当前使用的阈值。

要点

  • 每QALY成本效果阈值介于87美元(刚果民主共和国)至95958美元(美国)之间。
  • 每QALY阈值低于人均GDP的0.5倍者占低收入国家96%、中低收入国家76%、中高收入国家31%、高收入国家26%。
  • 每QALY阈值低于1倍人均GDP的国家有168个(97%),每生命年阈值低于1倍人均GDP的国家有171个(98%)。

核心结论

  • 基于广泛可得数据的方法可为利用经济评估进行资源分配决策的国家提供有用参考,并可丰富国际社会估算成本效果阈值的努力。
  • 研究结果显示的阈值低于许多国家当前使用的阈值。

研究设计与样本

  • 研究构建概念框架,评估具有给定增量成本效果比的新干预措施的采纳与覆盖对人群层面人均卫生支出增长率和预期寿命的影响。
  • 成本效果阈值的推导使新干预对预期寿命和人均卫生支出演变的影响设定在预设目标范围内。
  • 基于世界银行2010-19年数据,按收入水平预测174个国家的人均卫生支出和预期寿命增长,以提供成本效果阈值和长期趋势的指导。

主要发现

  • 每质量调整生命年(QALY)成本效果阈值介于87美元(刚果民主共和国)至95958美元(美国)之间。
  • 每QALY阈值低于人均国内生产总值(GDP)0.5倍者占低收入国家96%、中低收入国家76%、中高收入国家31%、高收入国家26%。
  • 每QALY阈值低于1倍人均GDP的国家有168个(97%),共174个国家。
  • 每生命年成本效果阈值介于78美元至80529美元之间,为人均GDP的0.12至1.24倍,低于1倍人均GDP的国家有171个(98%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Assessment of the efficiency of interventions is paramount to achieving equitable health-care systems. One key barrier to the widespread use of economic evaluations in resource allocation decisions is the absence of a widely accepted method to define cost-effectiveness thresholds to judge whether an intervention is cost-effective in a particular jurisdiction. We aimed to develop a method to estimate cost-effectiveness thresholds on the basis of health expenditures per capita and life expectancy at birth and empirically derive these thresholds for 174 countries. METHODS: We developed a conceptual framework to assess how the adoption and coverage of new interventions with a given incremental cost-effectiveness ratio will affect the rate of increase of health expenditures per capita and life expectancy at the population level. The cost-effectiveness threshold can be derived so that the effect of new interventions on the evolution of life expectancy and health expenditure per capita is set within predefined goals. To provide guidance on cost-effectiveness thresholds and secular trends for 174 countries, we projected country-level health expenditure per capita and life expectancy increases by income level based on World Bank data for the period 2010-19. FINDINGS: Cost-effectiveness thresholds per quality-adjusted life-year (QALY) ranged between US$87 (Democratic Republic of the Congo) and $95 958 (USA) and were less than 0·5 gross domestic product (GDP) per capita in 96% of low-income countries, 76% of lower-middle-income countries, 31% of upper-middle-income countries, and 26% of high-income countries. Cost-effectiveness thresholds per QALY were less than 1 GDP per capita in 168 (97%) of the 174 countries. Cost-effectiveness thresholds per life-year ranged between $78 and $80 529 and between 0·12 and 1·24 GDP per capita, and were less than 1 GDP per capita in 171 (98%) countries. INTERPRETATION: This approach, based on widely available data, can provide a useful reference for countries using economic evaluations to inform resource-allocation decisions and can enrich international efforts to estimate cost-effectiveness thresholds. Our results show lower thresholds than those currently in use in many countries. FUNDING: Institute for Clinical Effectiveness and Health Policy (IECS).

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Pichon-Riviere A, Drummond M, Palacios A, et al. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023. PMID: 37202020. doi:10.1016/S2214-109X(23)00162-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。